Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

AGEN vs ARIA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AGEN Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 9–1 Matrix Metrics)

AGEN Overall Winner 6-Pillar Tally: AGEN 5 – 0 ARIA (1 Tie) Matrix Metrics: AGEN 9 – 1 ARIA

As of Nov 16, 2026, Agenus Inc. (AGEN) is the stronger overall head-to-head candidate over ARIA (ARIA) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AGEN carries a Unified Composite Score of 52.4/100 (HOLD) at $6.29 (3.7x Forward P/E, 38.9% operating margin), whereas ARIA carries 47.7/100 (HOLD) at $21.03 (N/M Forward P/E, N/A operating margin).

  • Technical & Structure Timing Caution: AGEN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.5); meanwhile ARIA trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI N/A). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AGEN vs ARIA
AGEN NASDAQ Head-to-Head Winner
Agenus Inc.
Biological Products, (No Disgnostic Substances)
$6.29
-6.54% 1D
Market Cap $304.5M
TTM Revenue $34M
Forward P/E 3.7x
Beta / 30D Vol 1.61β · 76% Vol
Unified Composite Score
52.4 / 100 HOLD
Tech 44.0 Fund 53.0 Flow 66.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.9%), weak momentum, RSI 42
RSI-14: 41.5 · SMA20: $6.73 · SMA50: $7.33
ARIA US Equity
ARIA
Institutional Equity
$21.03
-3.52% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.92β · 43% Vol
Unified Composite Score
47.7 / 100 HOLD
Tech 50.0 Fund 52.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Trend telemetry aligned with daily close.
RSI-14: N/A · SMA20: N/A · SMA50: N/A

6-Pillar Scorecard Institutional Category Breakdown (AGEN 5 – 0 ARIA)

Columns: Metric · AGEN · ARIA
1. Valuation Multiples AGEN
Forward P/E 3.7x N/M
Trailing P/E 29.3x N/M
PEG Ratio 1.44x N/M
EV / Revenue 8.7x N/M
2. Growth & Scale AGEN
Revenue Growth (YoY) +4.1% N/A
Earnings Growth (YoY) -99.0% N/A
TTM Revenue (USD) $34M N/A
Market Cap $304.5M N/A
3. Profitability & Quality AGEN
Gross Margin N/A N/A
Operating Margin 38.9% N/A
Net Profit Margin 30.8% N/A
Return on Equity (ROE) -1278.8% N/A
4. Balance Sheet & Cash Flow AGEN
Cash Generation (TTM) -$35M N/A
Cash Flow Margin -103.7% N/A
Net Cash / Leverage $9.3M Net Cash N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AGEN
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 101.1% (13th %ile) N/A (N/A)
Put/Call OI Skew 0.02x (Call-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AGEN (9) vs ARIA (1)
Institutional Metric AGEN ARIA Criterion Row Edge
Market Capitalization
Scale
$304.5M N/A Larger Scale AGEN
Trailing P/E Ratio
Valuation
29.3x N/M Lower Multiple AGEN
Forward P/E Ratio
Valuation
3.7x N/M Lower Multiple AGEN
Revenue Growth (YoY)
Growth
+4.1% N/A Higher Growth AGEN
Operating Margin (TTM)
Profitability
38.9% N/A Higher Margin AGEN
Net Profit Margin
Profitability
30.8% N/A Higher Margin AGEN
Return on Equity (ROE)
Capital Efficiency
-1278.8% N/A Higher ROE AGEN
52-Week Range Position
Momentum
47% ($3–$10) 0% ($21–$27) Stronger Trend AGEN
Beta / 30D Volatility
Risk Regime
1.61β · 76% Vol 1.92β · 43% Vol Lower Realized Risk ARIA
Unified Institutional Score
Composite Signal
52.4 / 100 (HOLD) 47.7 / 100 (HOLD) Higher Composite AGEN
Trailing 12M Revenue (USD)
Operating Scale
$34M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.44x PEG · 8.7x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$35M ($9.3M Net Cash) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AGEN +15.69 pp
AGEN: +4.14% · ARIA: -11.55%
3M Horizon ARIA +0.26 pp
AGEN: -16.47% · ARIA: -16.21%
6M Horizon AGEN +6.83 pp
AGEN: -10.14% · ARIA: -16.97%
1Y Horizon AGEN +6.83 pp
AGEN: -10.14% · ARIA: -16.97%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AGEN vs ARIA. Trailing 12-month operating profitability (AGEN 38.9% vs ARIA N/A) and valuation multiples (AGEN 3.7x vs ARIA N/M Forward P/E) are benchmarked directly in Pillar 4 below.

AGEN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$34M
Gross MarginN/A
Op. Margin38.9%
ROE / Fwd P/E-1278.8% · 3.7x
ARIA ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AGEN BREAKDOWN
33d in phase · OBV NEUTRAL
Current IV 101.1%
IV Percentile 13th %ile
Put/Call OI Skew 0.02x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact AGEN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ARIA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ARIA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AGEN Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $304.5M market capitalization and 38.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ARIA Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ AGEN vs ARIA Key Questions & Quantitative Answers

As of Nov 16, 2026, Agenus Inc. (AGEN) is the stronger overall head-to-head candidate over ARIA (ARIA) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AGEN carries a Unified Composite Score of 52.4/100 (HOLD) at $6.29 (3.7x Forward P/E, 38.9% operating margin), whereas ARIA carries 47.7/100 (HOLD) at $21.03 (N/M Forward P/E, N/A operating margin). Technical & Structure Timing Caution: AGEN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.5); meanwhile ARIA trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI N/A). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

AGEN leads the Growth & Scale pillar: AGEN posts +4.1% YoY revenue growth and -99.0% YoY earnings growth on $34M TTM revenue (N/A gross margin, 38.9% operating margin), compared with ARIA at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, AGEN generates $34M in USD-normalized revenue versus N/A for ARIA. In operating R&D and SG&A reinvestment, AGEN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ARIA.

AGEN screens cheaper on headline valuation multiples. AGEN trades at 3.7x Forward P/E, 29.3x Trailing P/E, 1.44x PEG, and 8.7x EV/Revenue (-103.7% FCF margin), whereas ARIA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AGEN (-1278.8% ROE) versus ARIA (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, AGEN carries 101.1% implied volatility (13th %ile, Compressed (<25th %ile)), a 0.02x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.61β · 76% Vol realized risk). By comparison, ARIA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.92β · 43% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.